MCID: DRG026
MIFTS: 51

Drug Reaction with Eosinophilia and Systemic Symptoms

Categories: Blood diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Drug Reaction with Eosinophilia and Systemic Symptoms

MalaCards integrated aliases for Drug Reaction with Eosinophilia and Systemic Symptoms:

Name: Drug Reaction with Eosinophilia and Systemic Symptoms 53
Drug Rash with Eosinophilia and Systemic Symptoms 53 59
Drug Reaction Eosinophilic Systemic Syndrome 53 59
Dress Syndrome 53 59

Characteristics:

Orphanet epidemiological data:

59
drug rash with eosinophilia and systemic symptoms
Inheritance: Not applicable; Age of onset: All ages;

Classifications:



Summaries for Drug Reaction with Eosinophilia and Systemic Symptoms

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 139402Disease definitionDRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) is a hypersensitivity reaction characterized by a generalized skin rash, fever, eosinophilia, lymphocytosis and visceral involvement (hepatitis, nephritis, pneumonitis, pericarditis and myocarditis) and, in some patients, reactivation of human herpes virus 6.EpidemiologyPrevalence is unknown.EtiologyOnset usually occurs 2-6 weeks after administration of the causal medication. DRESS syndrome is most frequently associated with anticonvulsants and sulfonamides but other medications (allopurinol, cyclosporine, azathioprine, gold salts and antiviral agents) have also been implicated. The manifestations may persist for several weeks after withdrawal of the causative medication.Visit the Orphanet disease page for more resources.

MalaCards based summary : Drug Reaction with Eosinophilia and Systemic Symptoms, also known as drug rash with eosinophilia and systemic symptoms, is related to severe cutaneous adverse reaction and myocarditis. An important gene associated with Drug Reaction with Eosinophilia and Systemic Symptoms is CRP (C-Reactive Protein), and among its related pathways/superpathways are Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway and Downstream signaling in naive CD8+ T cells. The drugs leucovorin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are encephalitis and renal insufficiency

Wikipedia : 76 Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), also termed drug-induced... more...

Related Diseases for Drug Reaction with Eosinophilia and Systemic Symptoms

Diseases related to Drug Reaction with Eosinophilia and Systemic Symptoms via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 30.3 HLA-B TNF
2 myocarditis 30.3 HLA-B TNF
3 exanthem 30.2 CRP TNF
4 pneumonia 30.0 CRP TNF
5 adult-onset still's disease 30.0 CRP TNF
6 graft-versus-host disease 29.9 HLA-B TNF
7 familial mediterranean fever 29.9 CRP TNF
8 uveitis 29.9 HLA-B TNF
9 intermediate uveitis 29.9 HLA-B TNF
10 kawasaki disease 29.9 CRP TNF
11 diabetes mellitus 29.5 CRP HLA-B TNF
12 endocarditis 29.5 CRP TNF
13 brucellosis 29.5 CRP TNF
14 purpura 29.4 CRP TNF
15 panuveitis 29.4 HLA-B TNF
16 cytomegalovirus infection 29.4 HLA-B TNF
17 vasculitis 29.2 CRP HLA-B TNF
18 hypereosinophilic syndrome 11.1
19 allergic hypersensitivity disease 10.4
20 hepatitis 10.4
21 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.3
22 viral infectious disease 10.2
23 erythema multiforme 10.2
24 stevens-johnson syndrome/toxic epidermal necrolysis 10.2
25 glomerulonephritis 10.1
26 acute kidney tubular necrosis 10.1
27 agammaglobulinemia 10.1
28 dermatitis 10.1
29 pancreatitis 10.1
30 exfoliative dermatitis 10.1
31 tropical spastic paraparesis 10.0 HLA-B TNFRSF4
32 myositis 10.0
33 lung cancer 10.0
34 diabetes mellitus, insulin-dependent 10.0
35 enterocolitis 10.0
36 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.0
37 basal cell carcinoma 1 10.0
38 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
39 dermatofibrosarcoma protuberans 10.0
40 kala-azar 1 10.0
41 infantile liver failure syndrome 1 10.0
42 autoinflammation with infantile enterocolitis 10.0
43 acute liver failure 10.0
44 alopecia 10.0
45 hemophagocytic lymphohistiocytosis 10.0
46 lymphoma 10.0
47 angioimmunoblastic t-cell lymphoma 10.0
48 sialadenitis 10.0
49 interstitial nephritis 10.0
50 vogt-koyanagi-harada disease 10.0

Graphical network of the top 20 diseases related to Drug Reaction with Eosinophilia and Systemic Symptoms:



Diseases related to Drug Reaction with Eosinophilia and Systemic Symptoms

Symptoms & Phenotypes for Drug Reaction with Eosinophilia and Systemic Symptoms

Human phenotypes related to Drug Reaction with Eosinophilia and Systemic Symptoms:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 encephalitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002383
2 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
3 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
4 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
5 hepatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012115
6 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
7 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
8 thyroiditis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100646
9 nephrotic syndrome 59 32 occasional (7.5%) Occasional (29-5%) HP:0000100
10 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
11 macule 59 32 hallmark (90%) Very frequent (99-80%) HP:0012733
12 myocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012819
13 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
14 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
15 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0006554
16 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
17 erythroderma 59 32 hallmark (90%) Very frequent (99-80%) HP:0001019
18 eosinophilia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001880
19 cardiac arrest 59 32 hallmark (90%) Very frequent (99-80%) HP:0001695
20 immunologic hypersensitivity 59 32 hallmark (90%) Very frequent (99-80%) HP:0100326
21 pulmonary infiltrates 59 32 frequent (33%) Frequent (79-30%) HP:0002113
22 tubulointerstitial nephritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001970
23 angioedema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100665
24 pustule 59 32 occasional (7.5%) Occasional (29-5%) HP:0200039
25 interstitial pneumonitis 59 32 frequent (33%) Frequent (79-30%) HP:0006515
26 enanthema 59 32 occasional (7.5%) Occasional (29-5%) HP:0030249
27 lymphocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0100827
28 elevated hepatic transaminases 59 Frequent (79-30%)
29 elevated hepatic transaminase 32 frequent (33%) HP:0002910

Drugs & Therapeutics for Drug Reaction with Eosinophilia and Systemic Symptoms

Drugs for Drug Reaction with Eosinophilia and Systemic Symptoms (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
4 Anti-Bacterial Agents Phase 4
5 Antiprotozoal Agents Phase 4
6 Vitamin B9 Phase 4
7 Vitamin B Complex Phase 4
8 Antimalarials Phase 4
9 Anti-Infective Agents Phase 4
10 Folic Acid Antagonists Phase 4
11 Antiparasitic Agents Phase 4
12 Folate Phase 4
13 Immunoglobulins Phase 3
14 Antibodies Phase 3
15
Alprazolam Approved, Illicit, Investigational Phase 1 28981-97-7 2118
16 Psychotropic Drugs Phase 1,Not Applicable
17 Neurotransmitter Agents Phase 1,Not Applicable
18 Hypnotics and Sedatives Phase 1
19 GABA Agents Phase 1,Not Applicable
20 Tranquilizing Agents Phase 1,Not Applicable
21 Anti-Anxiety Agents Phase 1
22 GABA Modulators Phase 1
23 Central Nervous System Depressants Phase 1,Not Applicable
24
Clobetasol Approved, Experimental, Investigational Not Applicable 25122-46-7, 25122-41-2 5311051 32798
25
Prednisone Approved, Vet_approved Not Applicable 53-03-2 5865
26
Eslicarbazepine acetate Approved Not Applicable 75970-99-9, 236395-14-5 123618
27
Lamotrigine Approved, Investigational Not Applicable 84057-84-1 3878
28
Valproic Acid Approved, Investigational Not Applicable 99-66-1 3121
29
Carbamazepine Approved, Investigational Not Applicable 298-46-4 2554
30
Oxcarbazepine Approved Not Applicable 28721-07-5 34312
31 tannic acid Approved Not Applicable
32
Prednisolone phosphate Approved, Vet_approved Not Applicable 302-25-0
33
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Not Applicable 2921-57-5
35
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
36
Benzocaine Approved, Investigational Not Applicable 94-09-7, 1994-09-7 2337
37
Etanercept Approved, Investigational Not Applicable 185243-69-0
38
Allopurinol Approved Not Applicable 315-30-0 2094
39
Prednisolone hemisuccinate Experimental Not Applicable 2920-86-7
40 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
41 Emollients Not Applicable
42 Antineoplastic Agents, Hormonal Not Applicable
43 Hormone Antagonists Not Applicable
44 glucocorticoids Not Applicable
45 Hormones Not Applicable
46 Dermatologic Agents Not Applicable
47 Anti-Inflammatory Agents Not Applicable
48 Analgesics, Non-Narcotic Not Applicable
49 Analgesics Not Applicable
50 Cytochrome P-450 CYP3A Inducers Not Applicable

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
2 Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin) Terminated NCT00505648 Phase 3 Tegeline®
3 A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users Completed NCT03509285 Phase 1 Alprazolam Placebo;Cenobamate placebo;Alprazolam;Cenobamate
4 Comparison Between Corticosteroid and Topical Steroids in the DRESS Unknown status NCT01987076 Not Applicable Prednisone;Clobetasol
5 Severe Cutaneous Adverse Reactions in Thailand Unknown status NCT02574988
6 Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs Completed NCT02556320 Not Applicable anti-epileptic drug
7 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions Completed NCT01276314 Not Applicable anti- TNF-a;Prednisolone
8 T Cell Response in Hypersensitivity Syndrome Completed NCT00213447
9 An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
10 HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Recruiting NCT03046914 Not Applicable
11 Survey Study for Velaglucerase Alfa (VPRIV) in Japan Recruiting NCT03625882
12 Multiple Drug Hypersensitivity Syndrome Not yet recruiting NCT03784482

Search NIH Clinical Center for Drug Reaction with Eosinophilia and Systemic Symptoms

Genetic Tests for Drug Reaction with Eosinophilia and Systemic Symptoms

Anatomical Context for Drug Reaction with Eosinophilia and Systemic Symptoms

MalaCards organs/tissues related to Drug Reaction with Eosinophilia and Systemic Symptoms:

41
Skin, Testes, Thyroid, T Cells, Liver, Lung, Heart

Publications for Drug Reaction with Eosinophilia and Systemic Symptoms

Articles related to Drug Reaction with Eosinophilia and Systemic Symptoms:

(show top 50) (show all 309)
# Title Authors Year
1
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management. ( 30096127 )
2018
2
A familial mediterranean fever flare induced by a drug reaction with eosinophilia and systemic symptoms. ( 28653374 )
2018
3
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. ( 29133221 )
2018
4
Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. ( 29150836 )
2018
5
Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. ( 29242946 )
2018
6
Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. ( 29265576 )
2018
7
Use of antiviral medications in drug reaction with eosinophilia and systemic symptoms (DRESS): A case of infantile DRESS. ( 29334124 )
2018
8
Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection. ( 29367368 )
2018
9
Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. ( 29384118 )
2018
10
Drug Reaction with Eosinophilia and Systemic Symptoms Associated with Reactivation of Epstein-Barr Virus and/or Cytomegalovirus Leading to Hemophagocytic Syndrome in One of Two Patients. ( 29386835 )
2018
11
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive. ( 29387775 )
2018
12
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature. ( 29440628 )
2018
13
Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. ( 29512326 )
2018
14
Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). ( 29521632 )
2018
15
Drug Reaction with Eosinophilia and Systemic Symptoms: An Update and Review of Recent Literature. ( 29527023 )
2018
16
Up-regulation of Human Herpesvirus 6B-derived microRNAs in the Serum of Patients with Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. ( 29542806 )
2018
17
Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms. ( 29568844 )
2018
18
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to ethambutol. ( 29602678 )
2018
19
Drug reaction with eosinophilia and systemic symptoms syndrome induced by benznidazole. ( 29635801 )
2018
20
C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. ( 29656292 )
2018
21
Drug reaction with eosinophilia and systemic symptoms: DRESS syndrome. ( 29687681 )
2018
22
Classic autoimmune type 1 diabetes mellitus after a case of drug reaction with eosinophilia and systemic symptoms (DRESS). ( 29693052 )
2018
23
Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. ( 29744372 )
2018
24
Author's reply: Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms. ( 29796687 )
2018
25
Comment on: Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms. ( 29799057 )
2018
26
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. ( 29934423 )
2018
27
Drug reaction with eosinophilia and systemic symptoms caused by spironolactone: Case report. ( 30009386 )
2018
28
Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. ( 30023418 )
2018
29
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS. ( 30027105 )
2018
30
Predictors of disease severity in drug reaction with eosinophilia and systemic symptoms. ( 30058562 )
2018
31
A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit. ( 30069245 )
2018
32
Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement. ( 30099742 )
2018
33
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis. ( 30111350 )
2018
34
Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature. ( 30122752 )
2018
35
Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis. ( 30156263 )
2018
36
Reticular rash in drug reaction with eosinophilia and systemic symptoms syndrome: A clue to parvovirus B19 reactivation? ( 30167447 )
2018
37
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. ( 30176295 )
2018
38
Trimethoprim-sulfamethoxazole-induced drug reaction with eosinophilia and systemic symptoms in a child with congenital renal disease. ( 30187970 )
2018
39
Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. ( 30222854 )
2018
40
Reverse Isotopic Phenomenon in Drug Reaction with Eosinophilia and Systemic Symptoms. ( 30236950 )
2018
41
Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. ( 30240780 )
2018
42
Case of drug reaction with eosinophilia and systemic symptoms secondary to vancomycin. ( 30301733 )
2018
43
A case of Vogt-Koyanagi-Harada disease as a sequela of drug reaction with eosinophilia and systemic symptoms. ( 30306111 )
2018
44
Successful treatment of drug reaction with eosinophilia and systemic symptoms syndrome relapse with oral pulsed dexamethasone. ( 30364766 )
2018
45
Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. ( 30368475 )
2018
46
Abnormal Erythrocyte Morphology in Drug Reaction with Eosinophilia and Systemic Symptoms. ( 30403959 )
2018
47
Diclofenac induced drug rash with eosinophilia and systemic symptoms. ( 30055779 )
2018
48
Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. ( 29296640 )
2017
49
Drug rash with eosinophilia and systemic symptoms (DRESS) caused by phenytoin. ( 28830901 )
2017
50
Skin-Homing IL-13-Producing T Cells Expand in the Circulation of Patients with Drug Rash with Eosinophilia and Systemic Symptoms. ( 28601883 )
2017

Variations for Drug Reaction with Eosinophilia and Systemic Symptoms

Expression for Drug Reaction with Eosinophilia and Systemic Symptoms

Search GEO for disease gene expression data for Drug Reaction with Eosinophilia and Systemic Symptoms.

Pathways for Drug Reaction with Eosinophilia and Systemic Symptoms

Pathways related to Drug Reaction with Eosinophilia and Systemic Symptoms according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.02 TNF TNFRSF4
2
Show member pathways
10.74 TNF TNFRSF4
3 9.9 CRP TNF

GO Terms for Drug Reaction with Eosinophilia and Systemic Symptoms

Cellular components related to Drug Reaction with Eosinophilia and Systemic Symptoms according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.8 HLA-B TNF TNFRSF4

Biological processes related to Drug Reaction with Eosinophilia and Systemic Symptoms according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.33 HLA-B TNF TNFRSF4
2 defense response to Gram-positive bacterium GO:0050830 9.32 CRP TNF
3 tumor necrosis factor-mediated signaling pathway GO:0033209 9.26 TNF TNFRSF4
4 inflammatory response GO:0006954 9.13 CRP TNF TNFRSF4
5 negative regulation of lipid storage GO:0010888 8.62 CRP TNF

Sources for Drug Reaction with Eosinophilia and Systemic Symptoms

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....